CoChat

Striatal D2/D3 Receptor Occupancy, Clinical Response and Side Effects with Amisulpride: An Iodine-123-Iodobenzamide SPET Study

Meisenzahl, E., Schmitt, G., Gründer, G., Dresel, S., Frodl, T., la Fougère, C., Scheuerecker, J., Schwarz, M., Boerner, R., Stauss, J., Hahn, K., Möller, H.-J. · 2008 · Pharmacopsychiatry
Cited by 49

The DOI matches its Crossref record.

Abstract

INTRODUCTION: Amisulpride appears to be an effective atypical agent for treating schizophrenia in a dose-dependent manner. METHODS: 29 patients suffering from schizophrenia or schizoaffective disorder were treated with a broad dose range of amisulpride (50-1 200 mg/day, mean: 455.2+/-278.8 mg/day). After 2 weeks, brain single photon emission tomography (SPET) scans were performed two hours after intravenous injection of 185 MBq [123I]IBZM. Clinical evaluations and ratings of extrapyramidal symptoms were performed at baseline and after steady state treatment of two weeks with amisulpride. RESULTS: In patients treated with amisulpride, specific binding of [123I]IBZM to D2 receptors was significantly decreased (p<0.001) compared to healthy controls. D2 receptor blockade correlated well with administered doses and plasma concentrations of amisulpride. Extrapyramidal side effects, which had to be treated with biperiden, were observed in 31% of the patients. Clinical response was very good, without correlation between the response and striatal D2 occupancy. DISCUSSION: Within the first two weeks of treatment with the atypical antipsychotic amisulpride a significant occupancy of striatal postsynaptic dopamine D2 receptors was achieved. At the same time amisulpride shows an excellent tolerability with good efficacy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1055/s-2008-1076727

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 49

Metadata

Authors
Meisenzahl, E., Schmitt, G., Gründer, G., Dresel, S., Frodl, T., la Fougère, C., Scheuerecker, J., Schwarz, M., Boerner, R., Stauss, J., Hahn, K., & Möller, H.-J.
Venue
Pharmacopsychiatry
Published
2008-09
Volume
41
Issue
05
Pages
169-175
ISSN
  • 0176-3679 (ISSN-L)
  • 1439-0795
OpenAlex
W2017421170
Cited by
49
References
0
FWCI
2.92
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Striatal D2/D3 Receptor Occupancy, Clinical Response and Side Effects with Amisulpride: An Iodine-123-Iodobenzamide SPET Study. https://app.cochat.ai/papers/10.1055/s-2008-1076727
The paper
Meisenzahl, E., Schmitt, G., Gründer, G., Dresel, S., Frodl, T., la Fougère, C., Scheuerecker, J., Schwarz, M., Boerner, R., Stauss, J., Hahn, K., & Möller, H.-J. (2008). Striatal D2/D3 Receptor Occupancy, Clinical Response and Side Effects with Amisulpride: An Iodine-123-Iodobenzamide SPET Study. Pharmacopsychiatry. https://doi.org/10.1055/s-2008-1076727

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.